Holen Sie sich die Stockscreener-App
0.3285
0.90%
-0.003
Handel nachbörslich:
.31
-0.0185
-5.63%
Schlusskurs vom Vortag:
$0.3315
Offen:
$0.321
24-Stunden-Volumen:
31,068
Relative Volume:
0.01
Marktkapitalisierung:
$9.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.23M
KGV:
-2.2003
EPS:
-0.1493
Netto-Cashflow:
$-10.48M
1W Leistung:
+8.77%
1M Leistung:
-24.83%
6M Leistung:
-30.67%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.32
$0.3335
1-Wochen-Bereich:
$0.30
$0.3999
52-Wochen-Spanne:
$0.262
$9.1796
Curanex Pharmaceuticals Inc Stock (CURX) Company Profile
Firmenname
Curanex Pharmaceuticals Inc
Sektor
Branche
Telefon
718-673-6078
Adresse
2 JERICHO PLAZA,, JERICHO
Compare CURX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CURX
Curanex Pharmaceuticals Inc
|
0.3285 | 9.40M | 0 | -4.23M | -10.48M | -0.1493 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Curanex Pharmaceuticals Inc Aktie (CURX) Neueste Nachrichten
Curanex Pharmaceuticals Inc. Faces Investigation Over Securities Fraud - GuruFocus
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) - Weekly Voice
Investigation launched into potential securities fraud at Curanex Pharmaceuticals after volatile stock plunge. - Pluang
CURX Stock Price, Quote & Chart | CURANEX PHARMACEUTICALS INC (NASDAQ:CURX) - ChartMill
Curanex Pharmaceuticals Inc. Q1 2026 10-Q Report: Financials, Growth Strategy & Pipeline Expansion - Minichart
Curanex completes manufacturing, toxicology work for ulcerative colitis drug - Investing.com UK
Curanex completes manufacturing, toxicology work for ulcerative colitis drug By Investing.com - Investing.com South Africa
CURX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Curanex Advances Phyto-N Program and Expands Indications - TipRanks
Curanex Pharmaceuticals Advances Phyto-N Toward FDA Submission for Ulcerative Colitis and Expands Pipeline to Cancer Cachexia - Minichart
Curanex Pharmaceuticals advancing phyto-n toward a planned investigational new drug submission to FDA for ulcerative colitis in Q4 2026 - marketscreener.com
Curanex (Nasdaq: CURX) advances Phyto-N toward Q4 2026 IND and adds cancer cachexia - Stock Titan
Curanex Pharmaceuticals Advances Toward Q4 2026 IND Submission for Ulcerative Colitis and Expands Pipeline to Include Cancer Cachexia - Quiver Quantitative
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission - The Manila Times
Curanex Pharmaceuticals Inc 1Q 2026: Net income $(3.15M), EPS $(0.11) — 10-Q Summary - TradingView
Curanex (NASDAQ: CURX) ramps Phyto-N R&D as Nasdaq listing faces bid-price deadline - Stock Titan
TradingKey - TradingKey
Investigation launched into Curanex Pharmaceuticals over potential securities fraud after stock volatility. - Pluang
Curanex awaits quarterly results as investors monitor for potential updates, CURX shares steady in quiet trading session.Investment Signal Network - newser.com
Is Curanex (CURX) a once in a decade opportunity? (Volatility Increases) 2026-05-08Stock News - newser.com
Curanex Pharmaceuticals receives extension from Nasdaq to regain bid price compliance - Investing.com Nigeria
Curanex Granted Nasdaq Extension to Regain Listing Compliance - TipRanks
Curanex Pharmaceuticals given second Nasdaq bid-price compliance period through Nov. 2, 2026 - TradingView
[8-K] Curanex Pharmaceuticals Inc Reports Material Event - Stock Titan
Get insights into the top gainers and losers of Tuesday's after-hours session. - ChartMill
CURX Investors Have Opportunity to Join Curanex Pharmaceuticals Inc Fraud Investigation with ... - Caledonian Record
CURX Investors Have Opportunity to Join Curanex Pharmaceuticals Inc Fraud Investigation with the Schall Law Firm - GlobeNewswire
CURX Ownership | CURANEX PHARMACEUTICALS INC (NASDAQ:CURX) - ChartMill
CURANEX PHARMACEUTICALS INC (CURX) Fundamental Analysis & Valuation - ChartMill
Curanex (CURX) Stock: What Is Driving the Price (Momentum Building) 2026-04-20Real Time Stock Idea Network - UBND thành phố Hải Phòng
Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX - The Joplin Globe
These stocks are moving in today's pre-market session - ChartMill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Exclusive: Penny stock Curanex expands cachexia focus backed by patient recovery narratives - MSN
EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases - MSN
Curanex Pharmaceuticals Inc (CURX) stock price, news, quote and history - Yahoo Finance Singapore
Curanex Pharmaceuticals Inc (CURX) Latest Stock News & Headlines - Yahoo Finance
Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline - The Manila Times
Curanex Pharmaceuticals Reports Positive Patient Outcomes in Advanced Cancer and Critical Illness Cases Following Use of Lead Product - Quiver Quantitative
Five critically ill patient accounts inform Curanex's cachexia focus - Stock Titan
EXCLUSIVE: Penny Stock Curanex Expands Cachexia Focus Backed By Patient Recovery Narratives - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - benzinga.com
Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care - The Manila Times
Curanex Pharmaceuticals Highlights Patient Case Supporting Phyto-N's Potential in Cancer Cachexia Treatment - Quiver Quantitative
One cancer patient kept working 2+ years in Curanex Phyto-N case - Stock Titan
EXCLUSIVE: Curanex Highlights Case Study Supporting Cachexia Focus In Oncology Strategy - Benzinga
Top Curanex Pharmaceuticals (CURX) Competitors 2026 - MarketBeat
Curanex Pharmaceuticals Inc (CURX) latest stock news and headlines - Yahoo Finance Singapore
Finanzdaten der Curanex Pharmaceuticals Inc-Aktie (CURX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):